Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK known ✓ | P06239 | 2/20 | 0.60 |
| ▸ | KDR known ✓ | P35968 | 14/20 | 0.58 |
| ▸ | EGFR known ✓ | P00533 | 3/20 | 0.58 |
| ▸ | RET known ✓ | P07949 | 1/20 | 0.57 |
| ▸ | PDGFRA known ✓ | P16234 | 1/20 | 0.55 |
| ▸ | CSF1R known ✓ | P07333 | 2/20 | 0.54 |
| ▸ | PDGFRB known ✓ | P09619 | 1/20 | 0.54 |
| ▸ | FLT4 known ✓ | P35916 | 1/20 | 0.54 |
| ▸ | FLT3 known ✓ | P36888 | 1/20 | 0.54 |
| ▸ | MET known ✓ | P08581 | 2/20 | 0.53 |
| ▸ | KIF5B | P33176 | 1/20 | 0.57 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.53 |
| ▸ | AURKA | O14965 | 1/20 | 0.53 |
| ▸ | TEK | Q02763 | 1/20 | 0.53 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6512265 | 0.99 | LCK (0.61) | LCKKDREGFRRETKIF5B | |
| SCHEMBL2481753 | 0.84 | LCK (0.66) | LCKKDREGFRRETKIF5B | |
| SCHEMBL6506857 | 0.83 | KDR (0.66) | LCKKDREGFRRETKIF5B | |
| SCHEMBL4360537 | 0.83 | KDR (0.65) | LCKKDREGFRRETKIF5B | |
| SCHEMBL23158504 | 0.82 | MET (0.61) | LCKKDREGFRRETKIF5B | |
| SCHEMBL5824492 | 0.82 | LCK (0.67) | LCKKDREGFRRETKIF5B | |
| SCHEMBL23457663 | 0.81 | LCK (0.74) | LCKKDREGFRRETKIF5B | |
| SCHEMBL5201680 | 0.80 | KDR (0.65) | LCKKDREGFRRETKIF5B | |
| SCHEMBL198505 | 0.79 | PDGFRB (0.68) | KDREGFRPDGFRAPDGFRBMET | |
| SCHEMBL4365791 | 0.79 | KDR (0.74) | LCKKDREGFRRETKIF5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200392110-A1 | QUINOLINE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2020-12-17 | — | — | US | disclosed |
| EP-3415501-B9 | QUINOLINE DERIVATIVE | ONO PHARMACEUTICAL CO (JP) | 2020-12-02 | — | — | EP | disclosed |
| US-10676462-B2 | Quinoline derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2020-06-09 | — | — | US | disclosed |
| EP-3415501-B1 | QUINOLINE DERIVATIVE | ONO PHARMACEUTICAL CO (JP) | 2020-04-08 | — | — | EP | disclosed |
| US-10501442-B2 | Quinoline derivative | ONO PHARMACEUTICALS CO., LTD. (JP) | 2019-12-10 | — | — | US | disclosed |
| EP-3239147-B1 | QUINOLINE DERIVATIVE | ONO PHARMACEUTICAL CO (JP) | 2019-08-28 | — | — | EP | disclosed |
| US-20190135785-A1 | QUINOLINE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2019-05-09 | — | — | US | disclosed |
| US-10208034-B2 | Quinoline derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2019-02-19 | — | — | US | disclosed |
| US-10208022-B2 | Quinoline derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2019-02-19 | — | — | US | disclosed |
| EP-3415501-A1 | QUINOLINE DERIVATIVE | ONO Pharmaceutical Co., Ltd. (JP) | 2018-12-19 | — | — | EP | disclosed |
| US-20180258072-A1 | QUINOLINE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2018-09-13 | — | — | US | disclosed |
| US-9994549-B2 | Quinoline derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2018-06-12 | — | — | US | disclosed |
| US-20170349583-A1 | QUINOLINE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-12-07 | — | — | US | disclosed |
| EP-3239147-A1 | QUINOLINE DERIVATIVE | Ono Pharmaceutical Co., Ltd. (JP) | 2017-11-01 | — | — | EP | disclosed |
| US-20170088542-A1 | QUINOLINE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-03-30 | — | — | US | disclosed |
| US-9573935-B2 | Quinoline derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-02-21 | — | — | US | disclosed |
| US-20160168121-A1 | QUINOLINE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2016-06-16 | — | — | US | disclosed |
| EP-3026045-A1 | QUINOLINE DERIVATIVE | ONO Pharmaceutical Co., Ltd. (JP) | 2016-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200392110-A1 | QUINOLINE DERIVATIVE | FLT3, AXL, ERBB2 | LCK 4/4885KDR 27/4885EGFR 17/4885 |
| US-10501442-B2 | Quinoline derivative | FLT3, AXL, ERBB2 | LCK 4/4885KDR 27/4885EGFR 17/4885 |
| US-20170349583-A1 | QUINOLINE DERIVATIVE | FLT3, AXL, ABL1 | LCK 7/4885KDR 118/4885EGFR 42/4885 |
| US-20180258072-A1 | QUINOLINE DERIVATIVE | FLT3, AXL, ERBB2 | LCK 4/4885KDR 27/4885EGFR 17/4885 |
| US-10208022-B2 | Quinoline derivative | FLT3, AXL, ERBB2 | LCK 4/4885KDR 27/4885EGFR 17/4885 |
| US-20160168121-A1 | QUINOLINE DERIVATIVE | FLT3, AXL, ERBB2 | LCK 7/4885KDR 65/4885EGFR 24/4885 |
| US-20170088542-A1 | QUINOLINE DERIVATIVE | FLT3, AXL, ERBB2 | LCK 4/4885KDR 27/4885EGFR 17/4885 |
| US-10676462-B2 | Quinoline derivative | FLT3, AXL, ERBB2 | LCK 4/4885KDR 27/4885EGFR 17/4885 |
| US-20190135785-A1 | QUINOLINE DERIVATIVE | FLT3, AXL, ERBB2 | LCK 4/4885KDR 27/4885EGFR 17/4885 |
| US-10208034-B2 | Quinoline derivative | FLT3, AXL, ABL1 | LCK 7/4885KDR 118/4885EGFR 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.